Table 1:
Characteristics of eligible studies included in the meta-analysis
| Author | Year | Country | Ethnicity | Disease | Genotyping Methods | Sample Size (Case/Control) | Odds Ratio | LCI | UCI | HWE of Control |
|---|---|---|---|---|---|---|---|---|---|---|
| Borie R [1](9) | 2013 | France | Caucasian | IPF | Taqman | 142/1383 | 5.22 | 3.99 | 6.81 | 0.284 |
| Coghlan MA(10) | 2014 | USA | Caucasian | IPF | Taqman | 132/192 | 2.68 | 1.78 | 4.01 | N.A. |
| Fingerlin TA(11) | 2013 | UK/TX/etc | Non-hispanic |
|||||||
| White | IPF | Taqman | 2492/6573 | 4.51 | 3.91 | 5.21 | N.A. | |||
| Helling BA(12) | 2017 | USA | Caucasian | IPF | Taqman | 202/139 | 3.11 | 2.03 | 4.77 | 0.125 |
| Horimasu Y [1](13) | 2015 | Germany | Caucasian | IPF | Taqman | 71/35 | 11.05 | 3.3 | 36.99 | 0.791 |
| Horimasu Y [2](13) | 2015 | Japan | Asian | IPF | Taqman | 44/310 | 4.34 | 1.02 | 18.49 | 0.886 |
| Jiang H(14) | 2015 | China | Asian | IPF | Taqman | 187/250 | 1.93 | 1.32 | 2.82 | 0.01 |
| Kishore A [1](15) | 2016 | Czech | Caucasian | IPF | Taqman | 41/96 | 3.77 | 1.9 | 7.47 | N.A. |
| Kishore A [2](15) | 2016 | Germany | Caucasian | IPF | Taqman | 33/96 | 4.83 | 2.39 | 9.79 | N.A. |
| Kishore A [3](15) | 2016 | Greek | Caucasian | IPF | Taqman | 40/96 | 5.46 | 2.76 | 10.82 | N.A. |
| Kishore A [4](15) | 2016 | France | Caucasian | IPF | Taqman | 51/96 | 6.77 | 3.62 | 12.65 | N.A. |
| Noth I et al(16) | 2013 | USA | Caucasian | IPF | Taqman | 1410/1931 | 2.43 | 2.13 | 2.77 | N.A. |
| Seibold MA [1](5) | 2011 | USA | Caucasian | IPF | Taqman | 492/322 | 8.3 | 5.8 | 11.9 | N.A. |
| Stock CJ [1](17) | 2013 | UK | Caucasian | IPF | Taqman | 110/416 | 4.9 | 3.42 | 7.03 | N.A. |
| van der Vis JJ[1](18) | 2015 | Holland | Caucasian | IPF | Taqman | 115/249 | 3.63 | 2.38 | 5.55 | 0.426 |
| Wang C [1](19) | 2014 | China | Asian | IPF | Taqman | 165/1013 | 4.33 | 1.99 | 9.42 | 0.800 |
| Wei R [1](20) | 2014 | USA | Caucasian | IPF | Taqman | 84/689 | 3.2 | 2.21 | 4.63 | 0.556 |
| Zhang Y, et al(21) | 2011 | USA | Caucasian | IPF | Taqman | 341/802 | 4.18 | 3.35 | 5.22 | 0.447 |
| Borie R [2](9) | 2013 | France | Caucasian | Ssc- ILD | Taqman | 346/1383 | 1.05 | 0.8 | 1.37 | 0.284 |
| Borie R [3](9) | 2013 | Italy | Caucasian | Ssc- ILD | Taqman | 207/494 | 1.18 | 0.84 | 1.66 | 0.342 |
| Peljto A (22) | 2012 | USA | Caucasian | Ssc- ILD | Taqman | 109/122 | 1.02 | 0.55 | 1.91 | N.A. |
| Stock CJ [2](17) | 2013 | UK | Caucasian | Ssc- ILD | Taqman | 229/416 | 1.24 | 0.86 | 1.79 | N.A. |
| Horimasu Y [3](13) | 2015 | Germany | Caucasian | NSIP | Taqman | 31/35 | 8.44 | 2.34 | 30.47 | 0.791 |
| Horimasu Y [4](13) | 2015 | Japan | Asian | NSIP | Taqman | 30/310 | 2.08 | 0.24 | 18.14 | 0.886 |
| van der Vis JJ [3](18) | 2015 | Holland | Caucasian | NSIP | Taqman | 43/249 | 2.85 | 1.58 | 5.17 | 0.426 |
| Seibold MA [2](5) | 2011 | USA | Caucasian | FIP | Taqman | 83/322 | 6.2 | 3.7 | 10.4 | N.A. |
| van der Vis JJ [2](18) | 2015 | Holland | Caucasian | FIP | Taqman | 55/249 | 4.31 | 2.59 | 7.18 | 0.426 |
| Johnson C [2](23) | 2017 | USA | Caucasian | IIP | Taqman | 60/134 | 4.1 | 2.17 | 7.74 | N.A. |
IPF: idiopathic pulmonary fibrosis; ssc-ILD: systemic sclerosis-interstitial lung diseases; iNSIP: idiopathic nonspecific interstitial pneumonia; FIP: Familial interstitial pneumonia; IIP: idiopathic interstitial pneumonia; LCI: low confidence interval; UCI: upper confidence interval; HWE: Hardy-Weinberg equilibrium